A subcutaneous formulation will now be available to treat relapsing-remitting multiple sclerosis More: EU nod for new formulation of Biogen's Tysabri Source: News
read moreThe combination is not considered to be a cost-effective use of NHS resources in this setting More: NICE 'no' for Opdivo/Yervoy lung cancer combo Source: News
read moreThe drug was discovered through an AI-design platform within just eight months of project initiation More: Human trials for world's first AI-designed immuno-oncology drug Source: News
read moreThe drug failed to significantly reduce progression to ventilation or death in patients hospitalised with COVID-19 More: Lilly, Incyte's Olumiant fails in COVID-19 trial Source: News
read moreGilead snags full Trodelvy breast cancer nod, but it needs more to make the $21B Immunomedics buy worthwhile aliu Thu, 04/08/2021 – 11:49 More: Gilead snags full Trodelvy breast cancer nod, but it needs more to make the B Immunomedics
read moreLabeling glitch triggers yet another recall, this time for generic Tylenol fkansteiner Thu, 04/08/2021 – 11:41 More: Labeling glitch triggers yet another recall, this time for generic Tylenol Source: fierce
read more© 1994 - 2026 B.M. Pharmaceuticals